Literature DB >> 18063548

Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy.

Constance Visovsky1, Mary Collins, Linda Abbott, Julie Aschenbrenner, Connie Hart.   

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) continues to be a significant, debilitating symptom resulting from the administration of neurotoxic chemotherapy for the treatment of cancer. CIPN is an important consequence of cancer treatment because of its potential impact on physical functioning and quality of life. Oncology nurses play an important role in assessing, monitoring, and educating clients about CIPN. Despite investigations concerning pharmacologic and nonpharmacologic approaches to either preventing or minimizing the neurotoxicity resulting from certain chemotherapeutic agents, evidence to support the interventions is lacking. This article presents information concerning CIPN and summarizes the evidence for pharmacologic and nonpharmacologic approaches to the prevention and treatment of CIPN.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18063548     DOI: 10.1188/07.CJON.901-913

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  41 in total

1.  A retrospective study of the role of an occupational therapist in the cancer nutrition rehabilitation program.

Authors:  Josée Lemoignan; Martin Chasen; Ravi Bhargava
Journal:  Support Care Cancer       Date:  2009-12-04       Impact factor: 3.603

2.  Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.

Authors:  Sara Jane Ward; Sean D McAllister; Rumi Kawamura; Ryuchi Murase; Harshini Neelakantan; Ellen A Walker
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

3.  Chemotherapy-Induced Peripheral Neuropathy in Pediatric Cancer Patients.

Authors:  Rhonda J Moore; Hunter Groninger
Journal:  Cureus       Date:  2013-06-14

4.  Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare®) for chemotherapy-induced peripheral neuropathy.

Authors:  Thomas J Smith; Patrick J Coyne; Gwendolyn L Parker; Patricia Dodson; Viswanathan Ramakrishnan
Journal:  J Pain Symptom Manage       Date:  2010-12       Impact factor: 3.612

5.  Persistent mobility disability after neurotoxic chemotherapy.

Authors:  Elizabeth S Hile; G Kelley Fitzgerald; Stephanie A Studenski
Journal:  Phys Ther       Date:  2010-09-02

6.  Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial.

Authors:  Weidong Lu; Anita Giobbie-Hurder; Rachel A Freedman; Im Hee Shin; Nancy U Lin; Ann H Partridge; David S Rosenthal; Jennifer A Ligibel
Journal:  Oncologist       Date:  2019-10-14

7.  Evaluation of the Semmes-Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy.

Authors:  Delma Aurélia da Silva Simão; Antônio Lúcio Teixeira; Raissa Silva Souza; Elenice Dias Ribeiro de Paula Lima
Journal:  Support Care Cancer       Date:  2014-05-09       Impact factor: 3.603

8.  Effect of Gabapentin and Pregabalin in Rat Model of Taxol Induced Neuropathic Pain.

Authors:  A Mangaiarkkarasi; S Rameshkannan; R Meher Ali
Journal:  J Clin Diagn Res       Date:  2015-05-01

9.  Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).

Authors:  Katsumasa Kuroi; Kojiro Shimozuma; Yasuo Ohashi; Kazufumi Hisamatsu; Norikazu Masuda; Ayano Takeuchi; Toshihiko Aranishi; Satoshi Morita; Shozo Ohsumi; Frederick H Hausheer
Journal:  Support Care Cancer       Date:  2008-12-17       Impact factor: 3.603

10.  The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients.

Authors:  J S Hong; J Tian; L H Wu
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.